Evidence map›Paper›PMID 38399363›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia.

Zhiwei Huang, Lei Zhang, Yan Li, Yimin Yu, Yifeng Shen, Xiujia Sun, Kun Lou, Hongmei Luo, Zhibin Meng, Huafang Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhiwei HuangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.ORCID 0000-0002-7767-5167
Lei ZhangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Yan LiShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Yimin YuShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Yifeng ShenShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Xiujia SunShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Kun LouCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang 050000, China.
Hongmei LuoCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang 050000, China.
Zhibin MengCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang 050000, China.
Huafang LiShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Yumei WeiShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Shanghai Jiao Tong University · CNShijiazhuang Yiling Pharmaceutical (China) · CN

Funding

Clinical Research Plan of SHDC No. SHDC2023CRS016 and No. SHDC2022CRS032CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd NoneShanghai Clinical Research Center for Mental Health No. 19MC1911100Shanghai Jiao Tong University Medical-Industrial Interdisciplinary Fun YG2021QN131Shanghai Science Technology Development Funds No. 22S21902300
6 · The paper itself

Abstract

Currently, research predominantly focuses on evaluating clinical effects at specific time points while neglecting underlying patterns within the treatment process. This study aims to analyze the dynamic alterations in PANSS total scores and prolactin levels in patients with schizophrenia treated with risperidone, along with the influencing covariates. Using data from an 8-week randomized, double-blind, multicenter clinical trial, a population pharmacodynamic model was established for the PANSS total scores of and prolactin levels in patients treated with risperidone. The base model employed was the E

Indexed as

PANSS total scorespopulation pharmacodynamicsprolactinrisperidoneschizophrenia

Identifiers

PMID38399363
PMCPMC10891722
OpenAlexW4391145628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.